ArticleBMJ open2021
Model-based estimation of the economic burden of cholera in Africa.
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of cholera surveillance systems in Africa: a systematic review.Frontiers in epidemiology · 2024Pooled it
- Article
- Uptake likelihood assessment of oral cholera vaccine capsules: insights from stakeholder consultations in five countries.BMC public health · 2025Article
- Unmasking and tackling the underestimation of the cholera burden in Africa: A viewpoint.PLoS neglected tropical diseases · 2025Review
- Cholera Outbreak in Nigeria: History, Review of Socioeconomic and Meteorological Drivers, Diagnostic Challenges, and Artificial Intelligence Integration.Global health, epidemiology and genomics · 2025Review
- Cost of Cholera for Households and Health Facilities, Somalia.Journal of epidemiology and global health · 2024Article
- Unmasking the Neglected Cholera Outbreaks in Sub-Saharan Africa.International journal of public health · 2024Article
- Global economic burden per episode for multiple diseases caused by group A Streptococcus.NPJ vaccines · 2023Article
- The Chronic Cholera Situation in Africa: Why Are African Countries Unable to Tame the Well-Known Lion?Health services insights · 2023Article
- Advances in phage display based nano immunosensors for cholera toxin.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTo estimate the economic burden of cholera in Africa. SETTINGS: Cholera affected 44 countries in Africa.
participantsThe analysis used data from public sources in Africa published until September 2019.
methodsBased on existing data from field-based cost-of-illness studies, estimated cholera incidence rates, and reported cholera cases to WHO, this research estimates the economic burden of cholera in Africa from a societal perspective with 2015 as the base year. The estimate included out-of-pocket costs, public health system costs, productivity loss related to illness and an optional productivity loss related to premature deaths valued by the human capital approach. As various input data such as cholera incidence, hospitalisation rates and the number of workdays lost were not well defined, a series of scenario analyses and uncertainty analyses, accounting for unknowns and data variability, was conducted. Similarly, the value of time lost due to illness and deaths using the human capital approach was explored through scenario analyses.
resultsIn 2015, an estimated 1 008 642 cases in 44 African countries resulted in an economic burden of US$130 million from cholera-related illness and its treatment. When the estimated 38 104 cholera deaths were included in the analysis, the economic burden increased to US$1 billion or international $2.4 billion for the same year. At the same time, when only the 71 126 cases and 937 deaths reported to the WHO are considered, the economic burden was only US$68 million for the year 2015. The estimates of economic burden are thus heavily dependent on the cholera incidence rate, how time lost due to illness and deaths are calculated, hospitalisation rates and hospitalisation costs.
conclusionThe findings can be used as an economic justification for cholera control in Africa and for generating value-for-money evidence to underpin Ending Cholera-A Global Roadmap to 2030 with considerations to study limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.